AstraZeneca PLC or Exelixis, Inc.: Who Invests More in Innovation?

AstraZeneca vs. Exelixis: A Decade of Innovation Investment

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, AstraZeneca PLC has consistently outpaced Exelixis, Inc. in research and development (R&D) spending. From 2014 to 2023, AstraZeneca's R&D expenses grew by nearly 96%, reaching a peak of approximately $10.9 billion in 2023. In contrast, Exelixis, while showing a commendable increase, saw its R&D spending rise by over 900%, culminating in just over $1 billion in the same year.

A Closer Look at the Trends

AstraZeneca's investment in innovation has been robust, with a notable surge in 2021, where expenses jumped by 63% compared to the previous year. Meanwhile, Exelixis has shown a steady upward trend, reflecting its commitment to growth and innovation. This data highlights the strategic priorities of these companies, with AstraZeneca leading the charge in R&D investment, a critical driver for future breakthroughs.